Clinical Research Director - US

Novatim (Zhejiang) Pharmaceutical Technology Co., Ltd., established in 2018, is a biopharmaceutical technology company focused on the research and clinical application of innovative drugs in tumor immunotherapy. It is a wholly-owned subsidiary of Shanghai Keqi Pharmaceutical Technology Co., Ltd.
Based on clinical demand and focusing on tumor immunotherapy, the company has established research and development platforms for dual-function antibodies, dual-antibody ADC, solid tumor CAR-T, and hematological CAR-T, with the development of 10 FIC/BIC products.The company completed its first round of financing in 2022.
**Website: http://novatim-zj.cn/**Preparing to go outside China and recruit a local Clinical Research Director in the United States. This position is crucial as it will be the company's first hire in the U.S and it's a key role for their US plan.
Company Plans in the U.S.:No local entity or office currently exists;Planned that this director will be onboarding in May or June; then, will start to register the U.S. company entity. If all goes well, clinical trials will commence in August. Trials have already begun in China, so the progress of trials in the U.S. is expected to be faster.IPO planned for 2025; aiming for U.S. listing by 2026.